Literature DB >> 10996219

CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis.

N J Karandikar1, T N Eagar, C L Vanderlugt, J A Bluestone, S D Miller.   

Abstract

During the progression of relapsing experimental autoimmune encephalomyelitis (R-EAE), in SJL mice, disease relapses are mediated by T cells specific for non-cross-reactive myelin epitopes, a process termed 'epitope spreading'. CTLA-4, a negative regulator of T cell function modulates R-EAE, in that CTLA-4 blockade exacerbates clinical R-EAE. Herein, we show that CTLA-4-mediated signaling negatively regulates the dynamic spread of autoreactive T cell responses during the course of autoimmune disease. Anti-CTLA-4 mAb, administration at various points during the progression of R-EAE exacerbated subsequent clinical disease and enhanced T cell reactivity to both inducing and relapse-associated epitopes. In addition, CTLA-4 blockade during acute disease inhibited clinical remission. Thus, CTLA-4-mediated events are critical for intrinsic regulation of epitope spreading during autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996219     DOI: 10.1016/s0165-5728(00)00322-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  Mapping of the immunodominant T cell epitopes of the protein topoisomerase I.

Authors:  S Veeraraghavan; E A Renzoni; H Jeal; M Jones; J Hammer; A U Wells; C M Black; K I Welsh; R M du Bois
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 4.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

5.  PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.

Authors:  Bettina Schreiner; Samantha L Bailey; Tahiro Shin; Lieping Chen; Stephen D Miller
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

6.  SOCS3 deletion in T lymphocytes suppresses development of chronic ocular inflammation via upregulation of CTLA-4 and expansion of regulatory T cells.

Authors:  Cheng-Rong Yu; Sung-Hye Kim; Rashid M Mahdi; Charles E Egwuagu
Journal:  J Immunol       Date:  2013-10-07       Impact factor: 5.422

7.  Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients.

Authors:  K Ohkuma; T Sasaki; S Kamei; S Okuda; H Nakano; T Hamamoto; K Fujihara; I Nakashima; T Misu; Y Itoyama
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

8.  Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.

Authors:  Barbara Seitz-Polski; Guillaume Dolla; Christine Payré; Christophe A Girard; Joel Polidori; Kevin Zorzi; Eléonore Birgy-Barelli; Perrine Jullien; Cécile Courivaud; Thierry Krummel; Sylvia Benzaken; Ghislaine Bernard; Stéphane Burtey; Christophe Mariat; Vincent L M Esnault; Gérard Lambeau
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

Review 9.  Exploiting apoptosis for therapeutic tolerance induction.

Authors:  Daniel R Getts; Derrick P McCarthy; Stephen D Miller
Journal:  J Immunol       Date:  2013-12-01       Impact factor: 5.422

Review 10.  Immunoregulatory molecules are master regulators of inflammation during the immune response.

Authors:  Hortensia de la Fuente; Danay Cibrián; Francisco Sánchez-Madrid
Journal:  FEBS Lett       Date:  2012-07-20       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.